First Turn Management
Latest statistics and disclosures from First Turn Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SWAV, ARGX, CYTK, XENE, SRPT, and represent 22.68% of First Turn Management's stock portfolio.
- Added to shares of these 10 stocks: APGE (+$25M), SYRE (+$18M), ORIC (+$15M), KALV (+$14M), ATEC (+$14M), SWAV (+$13M), VKTX (+$11M), RCKT (+$6.8M), TYRA (+$6.3M), IRON (+$5.9M).
- Started 9 new stock positions in TYRA, APGE, ATEC, ORIC, SYRE, VKTX, RCKT, VERA, KALV.
- Reduced shares in these 10 stocks: Cymabay Therapeutics (-$35M), Karuna Therapeutics Ord (-$28M), CYTK (-$26M), , KRYS (-$20M), ROIV (-$15M), LEGN (-$14M), VRTX (-$9.6M), PCVX (-$6.6M), DAWN (-$6.3M).
- Sold out of its positions in CABA, Cymabay Therapeutics, PODD, Karuna Therapeutics Ord, Somalogic, ROIV.
- First Turn Management was a net seller of stock by $-45M.
- First Turn Management has $669M in assets under management (AUM), dropping by -4.00%.
- Central Index Key (CIK): 0001993440
Tip: Access up to 7 years of quarterly data
Positions held by First Turn Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for First Turn Management
First Turn Management holds 34 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Shockwave Med (SWAV) | 4.8 | $32M | +70% | 98k | 325.63 |
|
| Argenx Se Sponsored Adr (ARGX) | 4.7 | $32M | -4% | 80k | 393.72 |
|
| Cytokinetics Com New (CYTK) | 4.5 | $30M | -46% | 430k | 70.11 |
|
| Xenon Pharmaceuticals (XENE) | 4.4 | $29M | 680k | 43.05 |
|
|
| Sarepta Therapeutics (SRPT) | 4.3 | $29M | +8% | 222k | 129.46 |
|
| Axsome Therapeutics (AXSM) | 4.1 | $27M | +15% | 342k | 79.80 |
|
| Dex (DXCM) | 4.0 | $27M | 193k | 138.70 |
|
|
| Immunocore Hldgs Ads (IMCR) | 3.8 | $26M | +15% | 395k | 65.00 |
|
| Apogee Therapeutics (APGE) | 3.8 | $25M | NEW | 380k | 66.45 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.7 | $25M | -27% | 59k | 418.01 |
|
| Mirum Pharmaceuticals (MIRM) | 3.6 | $24M | +14% | 959k | 25.12 |
|
| Biohaven (BHVN) | 3.5 | $24M | -9% | 432k | 54.69 |
|
| Krystal Biotech (KRYS) | 3.5 | $23M | -45% | 131k | 177.93 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 3.4 | $23M | 152k | 151.17 |
|
|
| Transmedics Group (TMDX) | 3.3 | $22M | -7% | 297k | 73.94 |
|
| Day One Biopharmaceuticals I (DAWN) | 3.3 | $22M | -22% | 1.3M | 16.52 |
|
| Nuvalent Inc-a (NUVL) | 3.0 | $20M | +3% | 266k | 75.09 |
|
| Ionis Pharmaceuticals (IONS) | 2.7 | $18M | +18% | 422k | 43.35 |
|
| Vaxcyte (PCVX) | 2.7 | $18M | -27% | 260k | 68.31 |
|
| Spyre Therapeutics Com New (SYRE) | 2.6 | $18M | NEW | 464k | 37.93 |
|
| Ideaya Biosciences (IDYA) | 2.6 | $18M | +4% | 398k | 43.88 |
|
| Immunovant (IMVT) | 2.5 | $17M | 513k | 32.31 |
|
|
| Disc Medicine (IRON) | 2.4 | $16M | +60% | 253k | 62.26 |
|
| Verona Pharma Sponsored Ads (VRNA) | 2.3 | $16M | -19% | 973k | 16.09 |
|
| Oric Pharmaceuticals (ORIC) | 2.3 | $15M | NEW | 1.1M | 13.75 |
|
| Intra Cellular Therapies (ITCI) | 2.1 | $14M | -4% | 207k | 69.20 |
|
| Kalvista Pharmaceuticals (KALV) | 2.1 | $14M | NEW | 1.2M | 11.86 |
|
| Alphatec Hldgs Com New (ATEC) | 2.0 | $14M | NEW | 991k | 13.79 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.9 | $13M | -52% | 228k | 56.09 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.8 | $12M | +84% | 585k | 20.67 |
|
| Viking Therapeutics (VKTX) | 1.6 | $11M | NEW | 128k | 82.00 |
|
| Rocket Pharmaceuticals (RCKT) | 1.0 | $6.8M | NEW | 251k | 26.94 |
|
| Tyra Biosciences (TYRA) | 0.9 | $6.3M | NEW | 381k | 16.40 |
|
| Vera Therapeutics Cl A (VERA) | 0.8 | $5.1M | NEW | 118k | 43.12 |
|
Past Filings by First Turn Management
SEC 13F filings are viewable for First Turn Management going back to 2023
- First Turn Management 2024 Q1 filed May 6, 2024
- First Turn Management 2023 Q4 filed Feb. 8, 2024